Loading…
Biomerica, Inc. is projected to rise to $1.95 by 2027, a +15% move from its current price of $1.69. BMRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.65 | $1.69 | $1.73 | +0.02% |
| Jul 14 | $1.64 | $1.69 | $1.75 | +0.04% |
| Jul 15 | $1.62 | $1.69 | $1.76 | +0.06% |
| Jul 16 | $1.61 | $1.69 | $1.77 | +0.08% |
| Jul 17 | $1.61 | $1.69 | $1.78 | +0.10% |
| Jul 18 | $1.60 | $1.69 | $1.79 | +0.12% |
| Jul 19 | $1.59 | $1.69 | $1.80 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.59 | $1.69 | $1.80 | +0.13% |
| Week 2 | $1.55 | $1.69 | $1.85 | +0.27% |
| Week 3 | $1.52 | $1.70 | $1.89 | +0.40% |
| Week 4 | $1.50 | $1.70 | $1.92 | +0.54% |
| Week 5 | $1.48 | $1.70 | $1.95 | +0.67% |
| Week 6 | $1.46 | $1.70 | $1.98 | +0.81% |
| Week 7 | $1.45 | $1.71 | $2.01 | +0.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biomerica, Inc. is a biomedical technology company that develops, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. Its diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations.
The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
InFoods IBS uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria.
Biomerica, Inc. (BMRA) operates in the Healthcare sector as a biomedical technology company focusing on diagnostic and therapeutic products. The stock trades with a current price of $1.66 and a market capitalization of $5.13M, ranking at 5309 by market cap.
The near-term picture shows limited upside, while the longer horizon signals meaningful upside potential as reflected in the year-by-year forecast. The long-range outlook includes a path from a near-term plateau to a higher price trajectory into the 2030s and beyond, with increasing upside highlighted in the 2040s and 2050s.
A major floor 32.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.4% away) — a key level to hold.
The nearest ceiling, 43.8% above — a clean break opens room to run.
A major ceiling 60.0% above — clearing it would confirm fresh momentum.
Key BMRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BMRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.69 | Sell | $1.69 | Sell |
| MA 10 | $1.73 | Sell | $1.73 | Sell |
| MA 20 | $1.81 | Sell | $1.82 | Sell |
| MA 50 | $2.08 | Sell | $1.99 | Sell |
| MA 100 | $2.10 | Sell | $2.12 | Sell |
| MA 200 | $2.34 | Sell | $2.40 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.49 | Neutral |
| Stoch RSI (14) | 64.52 | Neutral |
| CCI (20) | -78.78 | Neutral |
| Williams %R (14) | -80.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -3.98 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 20.00 | Neutral |
| TRIX (15) | -0.88 | Sell |
| Awesome (5,34) | -0.31 | Sell |
| Ultimate (7,14,28) | 34.12 | Neutral |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 1.65 | Buy |
| ADX (14) | 33.50 | Sell |
| ATR (14) | 0.04 | Info |
The near-term technical picture remains neutral. The RSI(14) reads 30, and the stock trades with a 50-day simple moving average of $2.10 and a 200-day simple moving average of $2.35. Immediate support is at $1.66 and resistance at $2.47.
Over the last 30 days the price has traded between $1.42 and $1.95, defining a tight operational range with elevated volatility (annualized).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.65 | $1.69 | $2.16 | 0% | Neutral | |
| $1.57 | $1.95 | $2.54 | +15% | Neutral | |
| $1.54 | $1.96 | $2.64 | +16% | Neutral | |
| $1.50 | $1.94 | $2.68 | +15% | Neutral | |
| $1.59 | $2.09 | $2.96 | +24% | Bullish | |
| $1.60 | $2.13 | $3.07 | +26% | Bullish | |
| $1.86 | $2.52 | $3.69 | +49% | Bullish | |
| $2.11 | $2.89 | $4.30 | +71% | Bullish | |
| $2.01 | $2.80 | $4.22 | +66% | Bullish | |
| $2.00 | $2.81 | $4.29 | +67% | Bullish | |
| $2.74 | $4.07 | $6.57 | +141% | Bullish | |
| $4.31 | $7.04 | $12.31 | +317% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.65 | $1.69 | $2.02 | +0.00% |
| August 2026 | $1.43 | $1.68 | $2.03 | -0.40% |
| September 2026 | $1.45 | $1.72 | $2.09 | +2.18% |
| October 2026 | $1.50 | $1.78 | $2.18 | +3.41% |
| November 2026 | $1.48 | $1.76 | $2.18 | -0.84% |
| December 2026 | $1.45 | $1.74 | $2.16 | -1.49% |
Click any year to see its month-by-month BMRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BMRA could reach as high as $2.16, with a base case around $1.69 and support toward $1.65 — roughly 0% from $1.69. A consolidation phase looks the most probable path here.
Expect BMRA to range from $1.57 to $2.54 through 2027. The $1.95 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. Price action looks broadly range-bound.
The BMRA price prediction for 2028 points to an average of $1.96 (low $1.54, high $2.64) — a potential gain of +16% on today's $1.69. A consolidation phase looks the most probable path here.
In 2029, BMRA is projected to trade between $1.50 and $2.68, averaging $1.94 — a potential gain of +15% from today's $1.69. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
Biomerica, Inc.'s 2030 outlook centres on $2.09, within a $1.59 to $2.96 range. That is up +8% on the projected 2029 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, BMRA could reach as high as $3.07, with a base case around $2.13 and support toward $1.60 — roughly +26% from $1.69. Momentum favours further upside here.
Expect BMRA to range from $1.86 to $3.69 through 2032. The $2.52 average target implies a +49% move from current prices. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The BMRA price prediction for 2033 points to an average of $2.89 (low $2.11, high $4.30) — a potential gain of +71% on today's $1.69. Momentum favours further upside here.
In 2034, BMRA is projected to trade between $2.01 and $4.22, averaging $2.80 — a potential gain of +66% from today's $1.69. That is -3% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Biomerica, Inc.'s 2035 outlook centres on $2.81, within a $2.00 to $4.29 range. That is up 0% on the projected 2034 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2040, BMRA could reach as high as $6.57, with a base case around $4.07 and support toward $2.74 — roughly +141% from $1.69. Buyers look set to stay in control over this stretch.
Expect BMRA to range from $4.31 to $12.31 through 2050. The $7.04 average target implies a +317% move from current prices. That is up +73% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BMRA today (≈ 591.715976 BMRA) could be worth
$4,165.07
+$3,165.07 (+317%) by 2050 · US Dollar
Based on the average projected BMRA price of $7.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BMRAwould be worth at today's price.
$1,000 invested in BMRA on Jul 10, 2025 (≈ 299.401205 BMRA) would be worth
$505.99
-$494.01 (-49.4%) today · 0.51× · US Dollar
Based on a BMRA entry price of $3.34 vs. today's $1.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.75 | $965.71 | -3.4% |
| 1 month ago | $2.02 | $836.63 | -16.3% |
| 3 months ago | $2.13 | $793.43 | -20.7% |
| 6 months ago | $2.68 | $630.6 | -36.9% |
| 1 year ago | $3.34 | $505.99 | -49.4% |
| All time (5.0y) ago | $29.68 | $56.94 | -94.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BMRA forecast.
Our base-case forecast reaches $3.40 around 2040.
Implied market cap at $3.40: $10.51M
The multi-year forecast shows a shift from a neutral near-term stance to a bullish outlook as the horizon extends. In 2026 the price is forecast to average $1.66 with a flat path, while 2027–2029 show gradual upside and modest returns, culminating in 2030 with an average of $2.04 and a 22.7% ROI. From 2030 onward, the sentiment turns bullish with a rising price path: 2031 avg $2.05 (ROI 23.8%), 2032 avg $2.45 (ROI 47.5%), 2033 avg $2.82 (ROI 69.6%), 2034 avg $2.70 (ROI 62.6%), and 2035 avg $2.71 (ROI 63.4%).
The forecast accelerates into the 2040s and 2050, with 2040 avg $3.90 (ROI 135.2%) and 2050 avg $6.71 (ROI 304.5%), both labeled BULLISH. These projections suggest meaningful upside over the long term, albeit with inherent uncertainty and the usual cautions that projections are estimates, not guarantees.
Tap a question to reveal the answer.
2030 avg $2.04; min $1.54; max $2.89; ROI 22.7%; sentiment BULLISH.
The forecast shows a neutral path in the near term and a bullish trajectory starting in 2030, with 2030 avg $2.04 and 2050 avg $6.71; ROI reaches up to 304.5% in 2050. These are estimates and not guarantees.
Yes. The 2040 max is $6.36 and the 2050 max is $11.87, indicating a path that can exceed $5 on the way to the longer-term upside.
Min $1.66, Avg $1.66, Max $2.13; ROI 0; sentiment NEUTRAL.
2040 min $2.60; avg $3.90; max $6.36; ROI 135.2%; sentiment BULLISH.
Biomerica, Inc. Community Discussion
0Share your Biomerica, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.